Bio-Techne Corporation TECH
Regular-session close
After hours · Nov 20, 5:25 PM ET
- YTD
- +23.57%
- 1 year
- +23.74%
5D -0.15 (-0.21%)
- Market cap
- 11.42B
- Revenue (ttm)
- 1.23B
- Profit margin
- 14.00%
- EPS (ttm)
- 1.09
- Shares out
- 157.09M
- P/E ratio
- 66.67
- Forward P/E
- 31.43
- Dividend
- 0.32 (0.44%)
- Ex-dividend date
- Nov 13, 2026
- YTD return
- +23.57%
- 1-year return
- +23.74%
- Volume
- 3.66M
- Avg volume
- 2.91M
- Open
- 72.74
- Previous close
- 72.70
- Day's range
- 72.66 – 72.77
- 52-week range
- 43.30 – 72.84
- Beta
- 1.27
- Analysts
- Hold
- Price target
- 70.50 (-3.0%)
- Earnings date
- Feb 3, 2027
- 50-day average
- 72.57
Key statistics
- 200-day average
- 63.52
- Enterprise value
- 11.35B
- PEG ratio
- 2.17
- Price / sales
- 9.29
- Price / book
- 5.27
- Payout ratio
- 29.36%
- Revenue growth
- 4.60%
- Free cash flow
- 277.76M
- Total cash
- 351.13M
- Total debt
- 285.56M
- Return on equity
- 8.33%
- Short % of float
- 4.92%
Fundamental scorecard
19 of 25 checks passed on TECH’s reported financials
19of 25 checks passed
- Value 2 of 5
- Growth 5 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 50.00
- Target (mean)
- 70.50
- Target (high)
- 73.00
- Strong buy0
- Buy0
- Hold12
- Sell1
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 0.46971.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 0.49 | — | — | — |
| Nov 6, 2026 | Sep 30, 2026 | 0.44 | 0.44 | 0.00 | 0.00% |
| Aug 12, 2026 | Jun 30, 2026 | 0.519 | 0.52 | 0.00 | +0.19% |
| May 6, 2026 | Mar 31, 2026 | 0.55 | 0.53 | -0.02 | -3.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.43 | 0.46 | +0.03 | +6.98% |
| Nov 5, 2025 | Sep 30, 2025 | 0.4214 | 0.42 | 0.00 | -0.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 9, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Jun 30, 2026 | TD Cowen | down | Buy | Hold |
| Jun 30, 2026 | Benchmark | down | Buy | Hold |
| Jun 29, 2026 | Citigroup | down | Buy | Neutral |
| Jun 26, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bio-techne.com
News
CHANGED PUBLICATION DATE Q3 2026 RESULTS
Stock Market: Will S&P 500 Open Up or Down Today? Did Anthropic and its bankers get a key call wrong after IPO?
ASML vs. Broadcom: Which Tech Stock Is a Better Buy for 2027?
The AI boom had a really bad week — and it's raising loud alarms
Zelda Switch 2 restock: Live restock updates at Walmart, Target, and Best Buy (Nov. 22)
Anthropic shares slide as tech stock sell-off worsens
Cathie Wood buys $145.9 million of tumbling AI stock
Billionaire Tech Investor Philippe Laffont Just Loaded Up on These 4 AI Stocks
Atlanta’s Airport Has Massive Flight Delays. Expect More Tech ‘Glitches,’ Clayton Says.
Your note
Sign in to keep a note on TECH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director | Stock Award(Grant) | Oct 28, 2026 | 59,634 |
| BUSHMAN JULIE L. | Director | Stock Award(Grant) | Oct 28, 2026 | 11,525 |
| GEIST WILLIAM | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 24,943 |
| HIGGINS JOHN L | Director | Stock Award(Grant) | Oct 28, 2026 | 80,004 |
| HIPPEL JAMES | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 176,720 |
| KEEGAN JOSEPH D | Director | Stock Award(Grant) | Oct 28, 2026 | 18,161 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.07% | 14,250,400 | 1.04B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 10,250,628 | 744.91M | Sep 29, 2026 |
| HBK Investments L P | 4.92% | 7,732,128 | 561.89M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.04% | 6,348,862 | 461.37M | Sep 29, 2026 |
| FIL LTD | 3.99% | 6,272,729 | 455.84M | Sep 29, 2026 |
| State Street Corporation | 3.85% | 6,045,884 | 439.35M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 4,968,867 | 361.09M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.58% | 4,056,808 | 294.81M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,586,562 | 260.64M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.72% | 2,707,457 | 196.75M | Sep 29, 2026 |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 1.66% | 2,604,519 | 189.27M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,089,474 | 151.84M | Sep 29, 2026 |
